700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ ReadersThis Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Editorial Open Access
Esophageal cancer remains one of the most severe malignancies in terms of overall survival despite the introduction of novel radiation regimens and chemotherapy agents. Many of the patients are diagnosed in advanced cases in which a multimodal treatment protocol is applied, finding the biomarkers that are involved in the resistance to neoadjuvant treatment could select the subgroup of patients that could be submitted either to surgical treatment or to an experimental drug trial. Hereby, we reviewed the potential biomarkers (immunohistochemical, blood-based, miRNA markers and gene expression profiling) that promised novel therapeutic pathways protocols.
Esophageal cancer, Biomarkers, Neoadjuvant treatment, Immunohistochemistry, Gene expression, Esophageal Cancer